Glioblastoma Stem Cells at the Nexus of Tumor Heterogeneity, Immune Evasion, and Therapeutic Resistance
Cells · 09.04.2025 · 14 (8) · 562
DOI: 10.3390/cells14080562 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 09.04.2025. Verfasst von Justin Tang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Science, University of Guelph, Guelph, ON N1G 2W1, Canada. Hauptthemen laut MEDLINE: Glioblastoma, Neoplastic Stem Cells, Brain Neoplasms, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 127 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Glioblastoma (GBM) is an exceedingly aggressive primary brain tumor defined by rapid growth, extensive infiltration, and resistance to standard therapies. A central factor driving these malignancies is the subpopulation of glioblastoma stem cells (GSCs), which possess self-renewal capacity, multipotency, and the ability to regenerate tumor heterogeneity. GSCs contribute to key hallmarks of GBM pathobiology, including relentless progression, resistance to chemotherapy and radiotherapy, and inevitable recurrence. GSCs exhibit distinct molecular signatures, enhanced DNA repair, and metabolic adaptations that protect them against conventional treatments. Moreover, they reside within specialized niches—such as perivascular or hypoxic microenvironments—that sustain stemness, promote immunosuppression, and facilitate angiogenesis. Recent discoveries highlight signaling pathways like Notch, Wnt/β-catenin, Hedgehog, STAT3-PARN, and factors such as TFPI2 and HML-2 as critical regulators of GSC maintenance, plasticity, and immune evasion. These findings underscore the complexity of GSC biology and their pivotal role in driving GBM heterogeneity and therapeutic failure. Emerging therapeutic strategies aim to target GSCs through multiple avenues, including surface markers, immunotherapeutics (e.g., CAR T cells), metabolic vulnerabilities, and combination regimens. Advances in patient-derived organoids, single-cell omics, and 3D co-culture models enable more accurate representation of the tumor ecosystem and personalized therapeutic approaches. Ultimately, improved understanding of GSC-specific targets and the tumor microenvironment promises more effective interventions, paving the way toward better clinical outcomes for GBM patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biomedical Science, University of Guelph, Guelph, ON N1G 2W1, Canada.
- Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA.
Förderung
- NCI NIH HHS
Zitieren
APA
Tang, J., Amin, M. A., & Campian, J. L. (2025). Glioblastoma Stem Cells at the Nexus of Tumor Heterogeneity, Immune Evasion, and Therapeutic Resistance. Cells, 14(8), 562. https://doi.org/10.3390/cells14080562
Vancouver
Tang J, Amin MA, Campian JL. Glioblastoma Stem Cells at the Nexus of Tumor Heterogeneity, Immune Evasion, and Therapeutic Resistance. Cells. 2025;14(8):562. doi:10.3390/cells14080562
BibTeX
@article{Tang2025,
author = {Tang, Justin and Amin, Md Al and Campian, Jian L},
title = {Glioblastoma Stem Cells at the Nexus of Tumor Heterogeneity, Immune Evasion, and Therapeutic Resistance},
journal = {Cells},
year = {2025},
volume = {14},
number = {8},
pages = {562},
doi = {10.3390/cells14080562}
}
EUVIMED